Endotis signs licensing deal with Organon

Licensing agreement

Glycosciences specialist Endotis Pharma SA of Paris, has sealed a deal with the Dutch pharma company Organon to in license three anti-thrombotic compounds for onward development and commercialisation.

Under the terms of the agreement, Endotis has acquired exclusive rights to develop and commercialise Org 42675, Org 217609 and Org 224283, which are all anti-thrombotic compounds with novel dual mechanisms of action. Financial details were not disclosed.

Org 42675 and Org 217609 display both blood coagulation factor Xa inhibition and thrombin inhibition, while Org 224283 combines factor Xa inhibition and an antiplatelet effect, with both effects being neutralisable by a specific antidote.

Org 42675 has successfully completed two phase I clinical trials and Org 224283 is at a preclinical-stage of development.

Charles Woler, chairman and CEO of Endotis Pharma, said, “These compounds will strongly reinforce our position in thrombosis. Due to their oligosaccharide structure, they perfectly fit with our focus on small-glyco drugs. We are proud that Organon has faith in Endotis to develop these very promising compounds.”

David Nicholson, executive vice president for R&D at Organon, said, “Organon will continue to be involved bringing in our expertise in manufacturing and development. This deal maximizes the chances of bringing these innovative compounds to patients.”